Dr. Stephan Dorkhom is a distinguished, Triple-Board Certified Hematologist/Oncologist with over 15 years of experience in diagnosing, treating, and providing compassionate care for patients with blood disorders and cancer. He is recognized not only for his clinical expertise but also for his innovative contributions to cancer research and drug development.

Dr. Dorkhom earned his medical degree from a top-ranked institution, where he graduated with top honors, receiving numerous academic accolades for his exceptional performance. He continued his training at Memorial Sloan Kettering Cancer Center (MSKCC), one of the world’s leading cancer institutions, where he completed his residency in internal medicine. During his residency, he served as house staff, gaining invaluable experience in managing complex, high-acuity cases while learning from some of the most respected experts in oncology.

Following his residency, Dr. Dorkhom pursued a fellowship in hematology and oncology at MD Anderson Cancer Center (MDACC), widely regarded as a global leader in cancer care. During his fellowship, he developed a passion for molecular oncology and cancer genomics, focusing on uncovering the genetic foundations of cancer to enhance diagnostics and therapeutic approaches. His groundbreaking research during this period led to the identification of a novel cancer gene, which he helped translate into new drug development strategies. This discovery, in collaboration with researchers at the National Institutes of Health (NIH), was published in prestigious peer-reviewed journals and earned Dr. Dorkhom international recognition.

Transitioning into the pharmaceutical industry as a research scientist, Dr. Dorkhom bridged the gap between laboratory research and clinical practice. At a leading pharmaceutical company, he played a pivotal role in drug discovery, identifying promising lead compounds for cancer treatment. His deep understanding of molecular biology and pharmacology has been instrumental in advancing these therapies through preclinical stages and into clinical trials. He has co-authored several high-impact publications in major oncology journals, showcasing his contributions to personalized cancer therapies.

In addition to his research, Dr. Dorkhom has presented at prominent conferences, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO). As a first-author presenter, his work has been widely recognized for its potential to transform cancer care.

Dr. Dorkhom remains dedicated to delivering patient-centered, compassionate care, blending cutting-edge scientific knowledge with years of clinical expertise. He is committed to providing his patients with the most advanced treatment options while maintaining the highest standards of empathy and communication. Believing that every patient deserves not just the best medical treatment but also the utmost personal care, he takes a holistic approach to his practice.

A sought-after speaker and mentor, Dr. Dorkhom is dedicated to advancing the fields of hematology and oncology through education, research, and compassionate patient care. His career exemplifies his unwavering commitment to improving cancer treatment and patient outcomes, leaving a lasting impact in the fight against cancer.